<DOC>
	<DOC>NCT00400283</DOC>
	<brief_summary>This trial is conducted in Europe. A seven day dose escalation study in subjects with type 2 diabetes.</brief_summary>
	<brief_title>A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 diabetes Diet treatment only for at least two weeks Body mass index (BMI) between 2234 kg/m2 inclusive HbA1C between 6.512.0% inclusive Fasting blood glucose (FBG) between 7.018.0 mmol/L inclusive Patients should be negative (lesser than 70 kU/l) for antibodies against glutamic acid decarboxylase (GAD) Pharmacological treatment with medication or pancreatitis that the Investigator expected to interfere with blood glucose levels History of cancer or any clinically significant cardiovascular respiratory, hepatic, haematological, gastrointestinal, dermatological, venereal, neurological or psychiatric disorder as judged by the Investigator Impaired renal function, serum creatinine greater than 150Âµmol/L Patients, who were known to have serum hepatitis or who were carriers of the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies, or had a positive result to the test for HIV 1/2 antibodies Patients, who had received an investigational drug in the four months new chemical entity or licensed product preceding the start of dosing Patients, who had donated plasma or blood in the past month, or in excess of 500 mL in the past 12 weeks Patients who had a significant history of alcoholism or drug/chemical abuse</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>